Dermatology Online Journal · 2016 · 24 citations · 10 references
MedicineDermatologyPathologyAutoimmunityDermatopathologyImmunotherapyImmunopathology Of SkinImmunotherapy For Skin CancerInflammatory Skin DiseasesMelanocytic LesionsMelanoma PharmacotherapyMelanoma SurgeryAxillary Sentinel Lymph Node BiopsyMelanoma HistopathologyMelanoma ImmunotherapyPsoriasis PhototherapyPsoriasis TherapyPsoriatic DiseaseSuperficial Spreading MelanomaTumor Necrosis Factor Therapy
Melanoma occurrence during treatment with anti-tumor necrosis factor is considered an incidental event, although very recent studies suggest a risk. Etanercept is a fusion protein that binds the tumor necrosis factor receptor and is included among TNF inhibitors, approved for the treatment of several autoimmune diseases, such as psoriasis.We described a 79-year-old man with psoriasis, being treated with etanercept, who presented with a new brown to black macule on his right shoulder; this was immediately surgically excised. Histology showed a superficial spreading melanoma, 1.2 mm Breslow thickness, one mitosis/hpf, with no vascular or neural invasion (stage T2b). Sentinel lymph node biopsy was negative. There were no apparent melanoma risk factors: normal total nevus count, photo type IV, no childhood sunburns, no family history of melanoma, and no previous immune suppressive drugs and/or phototherapies. Etanercept 50 mg/week had been administered continuously for 5 years before the melanoma occurrence. After etanercept withdrawal his psoriasis slowly, but progressively relapsed.
10
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
S. Busco, Carlotta Buzzoni, Sandra Mallone et al. · PubMed · 2017 · 87 citations · Full text